Evidence map›Paper›PMID 39638971›Full record

ArticleCardiovascular and interventional radiology2025

Tumor Suppressor miR-34a: Potential Biomarker of TACE Response in HCC.

Jan Zavadil, Jaroslav Juracek, Barbora Cechova, Tomas Rohan, Jakub Husty, Ondrej Slaby, Martina Litschmannova, Michal Uher, S Nahum Goldberg, Tomas Andrasina

Abstract read
PubMed Publisher
In one paragraph

Article in Cardiovascular and interventional radiology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Jan ZavadilDepartment of Radiology and Nuclear Medicine, University Hospital Brno and Masaryk University Brno, Jihlavská 340/20, 625 00, Brno, Czechia.
Jaroslav JuracekCentral European Institute of Technology, Kamenice 753/5, 625 00, Brno, Czechia.
Barbora CechovaDepartment of Radiology and Nuclear Medicine, University Hospital Brno and Masaryk University Brno, Jihlavská 340/20, 625 00, Brno, Czechia.
Tomas RohanDepartment of Radiology and Nuclear Medicine, University Hospital Brno and Masaryk University Brno, Jihlavská 340/20, 625 00, Brno, Czechia.
Jakub HustyDepartment of Radiology and Nuclear Medicine, University Hospital Brno and Masaryk University Brno, Jihlavská 340/20, 625 00, Brno, Czechia.
Ondrej SlabyCentral European Institute of Technology, Kamenice 753/5, 625 00, Brno, Czechia.
Martina LitschmannovaDepartment of Applied Mathematics, Faculty of Electrical Engineering and Computer Science, VSB-Technical University of Ostrava, 17. Listopadu 2172/15, 708 00, Ostrava, Czechia.
Michal UherMasaryk Memorial Cancer Institute, Žlutý Kopec 543/7, 602 00, Brno, Czechia.
S Nahum GoldbergHadassah Hebrew University Medical Center, Ein Karem, Jerusalem, Israel.
Tomas AndrasinaDepartment of Radiology and Nuclear Medicine, University Hospital Brno and Masaryk University Brno, Jihlavská 340/20, 625 00, Brno, Czechia. andrasina.tomas@fnbrno.cz.ORCID http://orcid.org/0000-0001-5723-5175

Funding

Masarykova Univerzita MUNI/A/1222/2022Ministerstvo Zdravotnictví Ceské Republiky 16-31314AMinisterstvo Zdravotnictví Ceské Republiky 16-31765AMinisterstvo Zdravotnictví Ceské Republiky 65269705Vysoká Škola Bánská - Technická Univerzita Ostrava SP2023/011
6 · The paper itself

Abstract

purposeTACE induces variable systemic effects by producing factors that promote inflammation, oncogenesis, and angiogenesis. Here we compare concentrations of microRNAs (miR-21, miR-210 and miR-34a) and vascular endothelial growth factor (VEGF) in hepatocellular carcinoma (HCC) patients undergoing TACE with degradable (DSM) and nondegradable (DEB) particles and potential use of these biomarker changes for prediction of patient outcomes. MATERIALS AND

methodsOverall, 52 patients with HCC treated with DSM TACE (24 patients) and DEB TACE (28 patients) were included in this prospective study. Concentrations of studied biomarkers were measured from blood plasma preprocedurally, immediately (< 90 min) postprocedurally, and 24-h after TACE. Levels were compared between DSM and DEB TACE and correlated with treatment response six and 12 months after the first TACE.

resultsBoth DSM and DEB TACE elevated plasma levels of miR-21, miR-34a, and miR-210 at 24 h post-procedure compared to baseline levels (FC 1.25-4.0). MiR-34a elevation immediately after TACE was significantly associated with nonprogressive disease compared to those with progressive disease at both six months (FC

conclusionEmbolization particle type did not significantly impact miRNA or VEGF changes post-TACE. However, miR-34a elevation immediately after the procedure predicts better patient outcome and may prove useful as a biomarkers for the monitoring of clinical outcomes. LEVEL OF EVIDENCE: Level 3 Prospective cohort study.

Indexed as

Biomarkers, TumorCarcinoma, HepatocellularChemoembolization, TherapeuticLiver NeoplasmsMicroRNAsVascular Endothelial Growth Factor AAgedBiomarkersFemaleHumansMaleMiddle AgedProspective StudiesTreatment OutcomeBiomarkersBiomarkers, TumorMicroRNAsMIRN21 microRNA, humanMIRN34 microRNA, humanVascular Endothelial Growth Factor ADegradable and nondegradable particlesHepatocellular carcinomaHypoxiaMicroRNA and vascular endothelial growth factorTransarterial chemoembolizationTumor suppressor

Identifiers

PMID39638971

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.